Top 3 Marijuana Stocks to Buy After the Recent Correction

Marijuana Stocks

The sell-off in the market in recent days has affected stocks from almost all sectors, and in that regard, marijuana stocks have not been an exception. Many of the pot stocks in the market suffered considerable declines in recent days, and the latest selloff is particularly damaging since the stocks in the sector have performed poorly for many months now. All marijuana stocks have lost a minimum of 15-20% this year so far, and in fact, there are many stocks that have lost as much as 40% this year so far.

In this regard, it should be noted that while much of the recent declines could be laid at the door of the coronavirus pandemic, there are other issues that have plagued the industry as well. Poor sales, failure to make profits, the oversupply of product, and the slow rollout of stores are some of the factors behind the poor performance of marijuana stocks.

That being said, there are still some marijuana stocks that present value at this point in time. Investors could consider having a look at these stocks. Here is a look at three such marijuana stocks.

3 Marijuana Stocks to Buy: MediPharm Labs (TSX:LABS) (OTCQX:MEDIF)

Marijuana Stocks

One of the companies in the cannabis sector to have made rapid progress despite the slowdown in the sector is cannabis extraction services firm MediPharm Labs. The Canadian company provides extraction services to some of the biggest names in the industry and has a capacity to process 500,000 kilos of cannabis every year.

Rival extraction firm The Valens Company (TSXV:VLNS) (OTCQX:VLNCF) is gunning for an annual production capacity of 1 million kilos, but it is perhaps a good thing that MediPharm is not focused on expanding its capacity this aggressively. Lower production capabilities allow the company to be much more efficient in a difficult market.

>> Top 4 Cannabis Penny Stocks Under $5 to Watch This Week

Unlike many cannabis companies, MediPharm is profitable, and the secret of that lies in its various long-term contracts. MediPharm’s contracts have mostly all been signed for 12 months to 24 months, which helps the company to have a relatively predictable cash flow.

MediPharm stock is down 11% to $0.99 on Monday.

3 Marijuana Stocks to Buy: Organigram Holdings (TSX:OGI) (NASDAQ:OGI)

Another marijuana stock that could be in line to generate considerable returns in case of a recession in North America is Organigram Holdings. One of the most important things to keep in mind with regards to Organigram is that it only has one licensed production facility. This allows the company to run a tight ship and keep costs under control. Other companies have established a number of facilities and have found it difficult to regulate their production levels to match the market demand.

However, Organigram is also in the process of expanding its facility at Moncton and raise its production levels to as much as 113,000 kilos a year. It is also one of the most efficient cannabis producers, and at this point, the company has a yield of 230 grams per square foot.

Because of all this, the company does not have a lot of expenses coming up, and with the launch of cannabis 2.0, Organigram could start growing quickly, irrespective of an economic slowdown.

At the time of writing, Organigram stock is down by 10% at C$2.02.

3 Marijuana Stocks to Buy: Trulieve Cannabis Corp (CSE:TRUL) (OTC:TCNNF)

Marijuana Stocks

The United States-based multi-state operator, Trulieve Cannabis, is another company that has the possibility of thriving even if there is a recession. Unlike many other companies that have tried to move into as many markets as possible, Trulieve has focused on the markets in the United States where cannabis has been legalized. The company has been particularly aggressive with its move into Florida. 45 out of the 47 licensed dispensaries operated by Trulieve are located in Florida, and that has helped the company to corner a major portion of a key market.

Due to its fierce focus on the Florida market, Trulieve has built up its brand and, consequently, created a strong business. The company’s revenue in the first nine months of 2019 stood at $173.1 million, while its expenses came in at only $50.6 million.

In the same period, Trulieve managed to generate gross profits of as much as $111.5 million. Florida is a highly lucrative market, and if the company can maintain its hegemony in the Sunshine State, then it could continue to thrive. A recession may not have a major effect on its business and prospects.

Trulieve stock has lost over 12% this morning to C$8.23.

Final Thoughts

These are some of the stocks that could prove to be good picks. However, it should be noted that in the middle of a market selloff, it is often difficult to predict a bottom. Investors should consider the current crisis in the marijuana industry and the turmoil in the wider market before making a move.

>> Read More Investing & Finance News

Featured image: DepositPhotos © bloomua

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of or its officers. The author is wholly responsible for the validity of all statements. was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. does not render general or specific investment advice. Any information on should not be considered a recommendation to buy or sell any security. does not endorse or recommend the business, products, services or securities of any company mentioned on

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.